Document Detail

Effects of subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
MedLine Citation:
PMID:  8399659     Owner:  NLM     Status:  MEDLINE    
The use of recombinant human erythropoietin (rHuEPO) has revolutionized the treatment of renal anemia, but the dose regimens, the optimal frequency, and the effects on other target organs like the central nervous systems (CNS) are still under discussion. We designed a prospective, ongoing study with 10 stable continuous ambulatory peritoneal dialysis (CAPD) patients (6 males, 4 females; mean age 64.4 +/- 7.8 years), with a pretreatment hemoglobin (Hb) < 7.0 g% and requiring regular blood transfusions. Seven patients were treated with 4000 U rHuEPO once weekly (Eritrogen, Boehringer Mannheim), 2 patients received 4000 U every 5 and 8 days, and the last one 4000 U every 10 days. The target hematocrit was 33% and Hb 10.0 g%. The CNS activity was recorded as visual (VEP), brainstem (BAER), and somatosensory (SEP)-evoked potentials. The mean Hb concentration increased from 6.9 +/- 1.2 g% to 10.3 +/- 1.6 g% (p < 0.001) over 8 weeks. There were no significant changes in urea, creatinine, and potassium levels, and urine output. rHuEPO induced a decrease in latency of P100 VEP, in the four main components of BAER, and in the P27-N35 intertime of SEP. Parallel to the improvement of red cell indices, patients experienced a dramatic improvement in well-being. The subcutaneous administration of a single vial of rHuEPO is safe, convenient, and inexpensive in CAPD. The role of rHuEPO treatment in improving the electrophysiological brain function in uremic and anemic patients remains to be studied and may not necessarily be based on improved cerebral oxygenation.
B Di Paolo; A Marini; B Fiederling; L Di Liberato; P Santarelli; S Bucciarelli; S Stuard; L Paolantonio; A Albertazzi
Related Documents :
18552239 - Could solutions low in glucose degradation products preserve residual renal function in...
19574339 - Corynebacterium peritonitis in australian peritoneal dialysis patients: predictors, tre...
7503139 - The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism i...
8255009 - Effects of high-dose vitamin b6 therapy on microcytic and hypochromic anemia in hemodia...
17093379 - Successful desensitization of a case with desferrioxamine hypersensitivity.
8156509 - Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric c...
22627969 - Randomized clinical trial of ultrasound-guided foam sclerotherapy versus surgery for th...
25413389 - Five-fraction gamma knife radiosurgery using the extend relocatable system for benign n...
23688629 - Plasma metabolomic profiles predict near-term death among individuals with lower extrem...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis     Volume:  13 Suppl 2     ISSN:  0896-8608     ISO Abbreviation:  Perit Dial Int     Publication Date:  1993  
Date Detail:
Created Date:  1993-11-01     Completed Date:  1993-11-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8904033     Medline TA:  Perit Dial Int     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  S538-40     Citation Subset:  IM    
Department of Nephrology and Dialysis, University of Chieti, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  etiology,  physiopathology,  therapy
Erythropoietin / administration & dosage*
Evoked Potentials
Hemoglobins / analysis
Injections, Subcutaneous
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory*
Prospective Studies
Recombinant Proteins / administration & dosage
Uremia / complications,  therapy
Reg. No./Substance:
0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The initial decrease in effective peritoneal surface area is not caused by an increase in hematocrit...
Next Document:  Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal d...